Effect of Bisphosphonates on Bone Mineral Density After Renal Transplantation as Assessed by Bone Mineral Densitometry

Nayak, Brusabhanu; Guleria, Sandeep; Varma, Mukund; Tandon, Nikhil; Aggarwal, Sandeep; Bhowmick, D.; Agarwal, Sanjay Kumar; Mahajan, Sandeep; Gupta, Satish Chand; Sc, Tiwari

doi:10.1016/j.transproceed.2007.01.065

Cited by 15 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We showed that parenteral pamidronate, a second-generation aminobisphosphonate, preserved BMD but was associated with development of adynamic bone disease. 3 Although there have been several prospective studies reporting the effects of parenteral 4,5 and oral bisphosphonates [6][7][8][9] on BMD, there are few studies in renal transplant patients using risedronate, a commonly used third-generation aminobisphosphonate, and its effect on BMD and biochemical measures. 10,11 There are no studies of serial histomorphometry in renal transplant recipients using risedronate.…”

mentioning

confidence: 99%

Effect of Risedronate on Bone in Renal Transplant Recipients

Coco¹,

Pullman²,

Cohen

et al. 2012

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients. We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density (BMD) in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. There was no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.

show abstract

mentioning

confidence: 99%

Effect of Risedronate on Bone in Renal Transplant Recipients

Coco¹,

Pullman²,

Cohen

et al. 2012

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Several previous studies have shown that bisphosphonates continued to improved bone mineral density after renal transplantation [7]–[9], [31], [32] and most of them showed the effect on both lumbar spine and femoral neck BMD. In a meta-analysis review of 1209 patients [33], treatment with bisphosphonates increased BMD in lumbar spine and femoral neck.…”

Section: Discussionmentioning

confidence: 92%

“…Further, osteopenia is defined as a condition in which the difference between the mean BMDs of the patients and healthy young adults is between 1 and 2.5 SDs [6]. Several studies have shown the beneficial effects of bisphosphonates on post-transplantation osteoporosis [7]–[9]. Other studies have shown that calcineurin inhibitors (CIs) have deleterious effects on bone mineral metabolism in rats [10]–[12], and that at least one cyclosporine has a protective effect on bone [13].…”

Section: Introductionmentioning

confidence: 99%

Use of Alendronate Sodium (Fosamax) to Ameliorate Osteoporosis in Renal Transplant Patients: A Case-Control Study

et al. 2012

View full text Add to dashboard Cite

BackgroundRenal transplant patients often have severe bone and mineral deficiencies. While the clinical effects of immunosuppressive agents like calcineurin inhibitors (CIs) and sirolimus on bone turnover are unclear, bisphosphonates are effective in bone recovery in these patients. Gender is significantly associated with osteoporosis and affects bone turnover, which is different in women and men. The effective gender-related site of action of bisphosphonates is unknown.MethodsInitially, we enrolled 84 kidney recipients who had received their transplants at least 5 months ago; of these, 8 were excluded and 76 were finally included in the study. First bone mineral density (BMD) at the lumbar spine, hip, and femoral neck was determined using dual-energy X-ray absorptiometry (DXA) between September 2008 and March 2009. These 76 patients underwent a repeat procedure after a mean period 14 months. Immunosuppressive agents, bisphosphonates, patients' characteristics, and biochemical factors were analyzed on the basis of the BMD determined using DXA.ResultsAfter the 14-month period, the BMD of lumbar spine increased significantly (from 0.9 g/cm2 to 0.92 g/cm2, p<0.001), whereas that of the hip and femoral neck did not. Ordinal logistic regression analysis was used to show that Fosamax improved bone condition, as defined by WHO (p = 0.007). The use of immunosuppressive agents did not affect bone turnover (p>0.05). Moreover, in subgroup analysis, Fosamax increased the BMD at the lumbar spine and the hipbone in males (p = 0.028 and 0.03, respectively) but only at the lumbar spine in females (p = 0.022).ConclusionAfter a long periods after renal transplantation, the detrimental effects of steroid and immunosuppressive agents on bone condition diminished. Short-term Fosamax administration effectively improves BMD in these patients. The efficacy of Fosamax differed between male and female renal transplant patients.

show abstract

“…However, all pathologies associated with renal failure may not normalize even with good graft function. 1 Despite advances in patient and graft survivals after transplantation, persistent parathyroid and bone metabolic disorders are common complications. 2 Bone remodeling homeostasis is known to be defective.…”

mentioning

confidence: 99%